BBJ: The pharma sector is not yet one where Frame Group is present. Why and when would you like to enter it?

Attila Puskás: We believe timing and focus are essential to building long-term value. In the past decade, our activities have concentrated on areas where we could deliver measurable impact quickly: healthcare operations, industrial services, and infrastructure-related projects. That said, the pharmaceutical sector has always been of interest to us, due to its strong innovation culture and high standards. We see a growing demand for partners who can bring both operational excellence and fresh thinking into the supply chain and technical services around pharma. Entering the sector is, therefore, not a question of if, but of when. Our current strategy foresees that, as part of our regional expansion, we will begin building a presence in this industry within the next two to three years.

BBJ: Do you think technologies and practices you have developed for other fields (such as healthcare or industrial laundries) would be transferable, or would you have to start from scratch?

AP: We do not believe in reinventing the wheel where it is not necessary. Much of our experience is highly relevant to pharma. For example, in healthcare facilities and clean industrial environments, we have had to manage extremely strict hygiene standards, traceability systems, and regulatory compliance. The know-how we have gained in sterilization, technical facility management, and quality monitoring is directly transferable to pharmaceutical operations. Of course, we recognize that pharma has its own unique requirements and certifications, so some adaptation and new capabilities will be necessary. But we view this as an extension of what we already do well, not a step into the unknown.

BBJ: You have often said that what sets Frame Group apart is its mindset and commitment to quality. Do you see a market gap in the pharma sector among your competitors operating there, and is this an opportunity you would hope to exploit?

AP: Absolutely. Many large players in the pharma sector are highly competent but often slow-moving, and their scale can sometimes make them less agile. We see a market gap for a partner who combines rigorous quality standards with flexibility, speed, and a collaborative mindset. Our approach has always been to tailor solutions to the client’s real needs rather than push standardized packages. We believe this mindset, together with our proven operational track record, could make us a valuable partner in pharma, especially in Central and Eastern Europe, where the industry is growing rapidly and companies are actively looking for reliable service partners.

BBJ: Is there anything else you would like to add?

AP: Only that Frame Group’s journey has always been about building trust and long-term partnerships. Whether in healthcare, infrastructure, or, in the near future, pharma, we see ourselves as an enabler: helping clients focus on their core business while we ensure that critical operational and compliance areas are handled at the highest level. The pharma sector is a natural next step for us, and we look forward to contributing to its success with the same dedication and quality mindset that defines everything we do.

This article was first published in the Budapest Business Journal print issue of September 19, 2025.